EGFR, HER2 and HER4 are all possible dimerisation partners of HER3, but HER2 and HER3 form a particularly potent heterodimer, which is regarded as an oncogenic unit in many HER2-driven breast cancers [8], [9]. This evidence concerns the gene ERBB2 and breast carcinoma.